Group One Trading
PVLA

Group One Trading’s Palvella Therapeutics PVLA Stock Holding History

Group One Trading’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-188
Closed -$14.6K – 8307
2023
Q1 		$14.6K Hold
188
– – ﹤0.01% 5721
2022
Q4 		$15.6K Hold
188
– – ﹤0.01% 5760
2022
Q3 		$17K Buy
+188
New +$24.2K ﹤0.01% 6193
2022
Q2 		– Sell
-30
Closed -$7K – 8665
2022
Q1 		$7K Sell
30
-108
-78% -$28.4K ﹤0.01% 7330
2021
Q4 		$42K Sell
138
-147
-52% -$47.1K ﹤0.01% 6472
2021
Q3 		$118K Sell
285
-1,345
-83% -$468K ﹤0.01% 5749
2021
Q2 		$499K Buy
+1,630
New +$357K ﹤0.01% 4226
2019
Q4 		– Sell
-54
Closed -$15K – 5716
2019
Q3 		$15K Buy
+54
New +$20.9K ﹤0.01% 4469
2018
Q2 		– Sell
-6
Closed -$3K – 5552
2018
Q1 		$3K Buy
+6
New +$3.71K ﹤0.01% 4605

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Group One Trading's PVLA Position: Q1 2026 in Review

Group One Trading sold out of Palvella Therapeutics (PVLA) in Q1 2026, closing a stake of 332 shares — an estimated $34.6K sold.

Group One Trading first reported a position in PVLA in Q2 2019 and held it in 22 quarters. The position peaked at $362K in Q3 2021. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Group One Trading reported no remaining Palvella Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 332 Palvella Therapeutics shares in Q1 2026, an estimated $34.6K.
  • Group One Trading first reported a position in Palvella Therapeutics in Q2 2019 and held it in 22 quarters.
  • Group One Trading's Palvella Therapeutics position peaked at $362K in Q3 2021.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.